RB1 and TP53 pathways in radiation-induced sarcomas

Oncogene

Volumn 26, Issue 41, 2007, Pages 6106-6112

  Gonin Laurent, N ^a,b,c   Hadj Hamou, N S ^a,b,c   Vogt, N ^a,b,c   Houdayer, C ^a   Gauthiers Villars, M ^a   Dehainault, C ^a   Sastre Garau, X ^a   Chevillard, S ^d   Malfoy, B ^a,b,c  

^a INSTITUT CURIE   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

CDKN2A; Ionising radiation; MDMX; RB1; Sarcoma; TP53

Indexed keywords

ARF PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HUMAN; INFANT; POINT MUTATION; PRIORITY JOURNAL; RETINOBLASTOMA; SARCOMA; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

GENES, P53; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS, RADIATION-INDUCED; RETINOBLASTOMA PROTEIN; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548495555     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210404     Document Type: Article

References (29)

1. Aerts I, Pacquement H, Doz F, Mosseri V, Desjardins L, Sastre X et al. (2004). Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 40: 1522-1529.
2. Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK et al. (2004). Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 203: 762-770.
3. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R et al. (2004). Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24: 5835-5843.
4. Gonin-Laurent N, Gibaud A, Huygue M, Lefevre SH, Le Bras M, Chauveinc L et al. (2006). Specific TP53 mutation pattern in radiation-induced sarcomas. Carcinogenesis 27: 1266-1272.
5. Goodrich DW. (2006). The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene 25: 5233-5243.
6. Houdayer C, Gauthier-Villars M, Lauge A, Pages-Berhouet S, Dehainault C, Caux-Moncoutier V et al. (2004). Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat 23: 193-202.
7. Kato MV, Shimizu T, Ishizaki K, Kaneko A, Yandell DW, Toguchida J et al. (1996). Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett 106: 75-82.
8. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C et al. (2006). DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 19: 106-114.
9. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Tamiya S, Takahira T et al. (2003). Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 201: 487-495.
10. Kawaguchi K, Oda Y, Sakamoto A, Saito T, Tamiya S, Iwamoto Y et al. (2002). Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol 15: 878-888.
11. Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M et al. (2005). Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23: 2272-2279.
12. Knudson AG. (2001). Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162.
13. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C et al. (2006). Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61-66.
14. Lavin MF, Gueven N. (2006). The complexity of p53 stabilization and activation. Cell Death Differ 13: 941-950.
15. Lefèvre SH, Vogt N, Dutrillaux AM, Chauveinc L, Stoppa-Lyonnet D, Doz F et al. (2001). Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma. Oncogene 20: 8092-8099.
16. Marine JC, Jochemsen AG. (2004). Mdmx and Mdm2: brothers in arms? Cell Cycle 3: 900-904.
17. Menu-Branthomme A, Rubino C, Shamsaldin A, Hawkins MM, Grimaud E, Dondon MG et al. (2004). Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood. Int J Cancer 110: 87-93.
18. Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler HP. (1996). Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 122: 559-565.
19. Moysich KB, Menezes RJ, Michalek AM. (2002). Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. Lancet Oncol 3: 269-279.
20. Patino-Garcia A, Sierrasesumaga L. (1997). Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet 98: 50-55.
21. Perucca-Lostanlen D, Rostagno P, Grosgeorge J, Marcie S, Gaudray P, Turc-Carel C. (2004). Distinct MDM2 and P14ARF expression and centrosome amplification in well-differentiated liposarcomas. Genes Chromosomes Cancer 39: 99-109.
22. Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG. (2001). Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 61: 1839-1842.
23. Sartor M, Steingrimsdottir H, Elamin F, Gaken J, Warnakulasuriya S, Partridge M et al. (1999). Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer 80: 79-86.
24. Sharpless NE. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576: 22-38.
25. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D et al. (2006). Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 94: 561-568.
26. Toledo F, Wahl GM. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923.
27. Travis LB. (2002). Therapy-associated solid tumors. Acta Oncol 41: 323-333.
28. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. (2000). Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120: 91-98.
29. Wakeford R. (2004). The cancer epidemiology of radiation. Oncogene 23: 6404-6428.